Pharmaust Ltd
ASX:PAA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Pharmaust Ltd
Inventory
Pharmaust Ltd
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharmaust Ltd
ASX:PAA
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Inventory
AU$50.6m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Inventory
AU$15.1m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
16%
|
CAGR 10-Years
9%
|
|
Pharmaust Ltd
Glance View
PharmAust Ltd. is a pharmaceutical company, which provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2001-10-05. The firm is focused on developing therapeutics for cancer, neurodegenerative diseases and viral infections in humans and cancer for pet dogs. The firm's lead candidate, monepantel (MPL), is a small molecule drug primarily being developed as a safe and potent treatment for cancer. The MPL can also be used for neurodegenerative diseases such as Motor Neuron Disease, Parkinson's Disease, and Alzheimer's Disease. The company has completed Phase I clinical trials with MPL in humans and dogs diagnosed with solid tumors. The firm has also initiated a preclinical program to screen its portfolio of aminoacetonitrile (AAD) compounds for anticancer activity.
